

Redaction & Confidentiality Log to Supplemental Requests

Per OAR 409-070-0070 and other applicable law, this document identifies those documents that are exempt from public disclosure and explains the grounds for such exemption. Under OAR 409-070-0070(2), “Confidential materials filed by an applicant in connection with a [HCMO] transaction that is subject to review by . . .the [Oregon Health] Authority . . . shall be maintained as confidential materials in accordance with . . . ORS 415.501(13)(c).” Under ORS 415.501(13)(c), the Oregon Health Authority “shall maintain the confidentiality of all confidential information and documents that are not publicly available that are obtained in relation to a [HCMO] material change transaction.” Such information is “exempt from disclosure under ORS 192.311 to 192.478 [the Public Records Act].” The documents and information identified below are confidential and contain information that is not publicly available. Thus, the Oregon Health Authority shall maintain the confidentiality of such documents and shall not release any such documents under the Oregon Public Records Act.

This document in no way limits either party’s right to assert additional or alternative grounds for exemption from the Oregon Public Records Act. The Parties respectfully request highly confidential treatment under all applicable statutes, rules, and regulations. Without prejudice to the rights of VaxCare Holdings, LLC and its subsidiaries (“VaxCare”) or Act II Holdings L.P. (“Buyer”), if the Oregon Health Authority or Department of Justice should at any time contemplate disclosing any such materials to the public or to any third party for any reason and for any use—including but not limited to quoting from, attaching, or otherwise referring to such documents in a court or administrative proceeding whether filed under seal or publicly—we request an opportunity of no fewer than three days advance notice to allow sufficient time to object and, if necessary, seek protections against disclosure from a court of competent jurisdiction.

<u>Bates Reference</u>	<u>Party Information</u>	<u>Information Requested</u>	<u>Information Redacted</u>	<u>Basis for Redaction</u>
HCMO_SUBMISSION_000625	VaxCare	Supplemental Materials	Oregon Clients	VaxCare requests confidential treatment of this document. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would enable competitors to identify and exploit vulnerabilities in the company's governance model. Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, VaxCare is requesting further confidential treatment of this document unless VaxCare provides its written consent to publication. This information is also protected from disclosure by ORS 192.345(2); ORS 192.355(9)(a); and ORS 646.461 et seq.
HCMO_SUBMISSION_000626 through HCMO_SUBMISSION_000648	VaxCare	Supplemental Materials	VaxCare Terms of Service	VaxCare requests confidential treatment of this document. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would enable competitors to identify and exploit vulnerabilities in the company's governance model. Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, VaxCare is requesting further confidential treatment of this document unless VaxCare provides its written consent to publication. This information is also protected from disclosure by ORS 192.345(2); ORS 192.355(9)(a); and ORS 646.461 et seq.
HCMO_SUBMISSION_000649	VaxCare	Supplemental Materials	List of Consultants or Advisors	VaxCare requests confidential treatment of this document. As a nonpublic entity, this information has not been made publicly available in any other forum. This is confidential information submitted in confidence that could be used by others for business advantage. Further, this information is competitively sensitive, and disclosure would enable competitors to identify and exploit vulnerabilities in the company's governance model. Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, VaxCare is requesting further confidential treatment of this document unless VaxCare provides its written consent to publication. This information is also protected from disclosure by ORS 40.225, 40.227, 192.345(2); ORS 192.355(9)(a); and ORS 646.461 et seq.
HCMO_SUBMISSION_000650	Buyer	Supplemental Materials	List of Consultants or Advisors	Buyer requests confidential treatment of this document. As a nonpublic entity, this information has not been made publicly available in any other forum. This is confidential information submitted in confidence that could be used by others for business advantage. Further, this information is competitively sensitive, and disclosure would enable competitors to identify and exploit vulnerabilities in the Buyer's governance model. The information is being produced solely because of requirements of the HCMO program and is otherwise non-public and not for disclosure. Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, Buyer is requesting further confidential treatment of this

<u>Bates Reference</u>	<u>Party Information</u>	<u>Information Requested</u>	<u>Information Redacted</u>	<u>Basis for Redaction</u>
				document unless Buyer provides its written consent to publication. This information is also protected from disclosure by ORS 40.225, 40.227, 192.345(2); ORS 192.355(9)(a); and ORS 646.461 et seq.
HCMO_SUBMISSION_000651	Buyer	Supplemental Materials	Projections	Buyer requests confidential treatment of this document. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, has actual and potential commercial value, and could be used by others for business advantage. The information is known to a limited number of employees. The information is being produced solely because of requirements of the HCMO program and is otherwise non-public and not for disclosure. Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, Buyer is requesting further confidential treatment of this document unless Buyer provides its written consent to publication. This information is also protected from disclosure by ORS 192.345(2); ORS 192.355(9)(a); and ORS 646.461 et seq.